Bausch + Lomb (NYSE:BLCO) Stock Lifted to “Strong-Buy” by Wall Street Zen

Wall Street Zen upgraded shares of Bausch + Lomb (NYSE:BLCO) from a buy rating to a strong-buy rating in a report released on Saturday morning,Wall Street Zen reports.

BLCO has been the subject of several other reports. Leerink Partners began coverage on Bausch + Lomb in a research note on Wednesday, September 9th. They issued an “outperform” rating and a $24.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $21.00 target price on shares of Bausch + Lomb in a research report on Friday, August 28th. Wells Fargo & Company boosted their target price on Bausch + Lomb from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research report on Thursday. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $20.00 target price on shares of Bausch + Lomb in a report on Thursday. Finally, Evercore set a $17.00 price target on Bausch + Lomb in a research report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $20.75.

Bausch + Lomb Stock Down 2.0%

BLCO stock opened at $19.99 on Friday. The company has a current ratio of 1.56, a quick ratio of 1.02 and a debt-to-equity ratio of 0.78. The company’s 50-day moving average price is $17.35 and its 200 day moving average price is $16.69. Bausch + Lomb has a 52 week low of $14.44 and a 52 week high of $21.36. The company has a market cap of $7.14 billion, a P/E ratio of -64.48, a P/E/G ratio of 0.59 and a beta of 0.56.

Bausch + Lomb (NYSE:BLCO) last issued its earnings results on Wednesday, October 28th. The company reported $0.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.21 by $0.13. Bausch + Lomb had a negative net margin of 2.05% and a positive return on equity of 5.01%. The company had revenue of $1.38 billion during the quarter, compared to analysts’ expectations of $1.37 billion. During the same period last year, the company posted $0.18 earnings per share. The firm’s quarterly revenue was up 7.3% compared to the same quarter last year. On average, research analysts expect that Bausch + Lomb will post 0.94 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Eschenbach Andrew C. Von sold 6,059 shares of Bausch + Lomb stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $16.58, for a total transaction of $100,458.22. Following the completion of the transaction, the director directly owned 63,733 shares in the company, valued at $1,056,693.14. The trade was a 8.68% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO Frederick Munsch sold 52,900 shares of Bausch + Lomb stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $16.78, for a total value of $887,662.00. Following the transaction, the chief accounting officer owned 45,831 shares of the company’s stock, valued at $769,044.18. This represents a 53.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 71,459 shares of company stock worth $1,194,370 in the last ninety days. Insiders own 1.45% of the company’s stock.

Institutional Investors Weigh In On Bausch + Lomb

Large investors have recently bought and sold shares of the stock. Engineers Gate Manager LP acquired a new position in shares of Bausch + Lomb in the second quarter worth $1,479,000. Beach Point Capital Management LP purchased a new stake in shares of Bausch + Lomb in the third quarter valued at $5,882,000. Whitebox Advisors LLC boosted its stake in shares of Bausch + Lomb by 15.8% during the first quarter. Whitebox Advisors LLC now owns 1,101,854 shares of the company’s stock valued at $17,519,000 after acquiring an additional 150,641 shares during the last quarter. Sei Investments Co. boosted its stake in shares of Bausch + Lomb by 100.0% during the first quarter. Sei Investments Co. now owns 139,266 shares of the company’s stock valued at $2,214,000 after acquiring an additional 69,633 shares during the last quarter. Finally, Counterpoint Mutual Funds LLC acquired a new stake in shares of Bausch + Lomb during the third quarter valued at $670,000. Institutional investors and hedge funds own 11.07% of the company’s stock.

Key Stories Impacting Bausch + Lomb

Here are the key news stories impacting Bausch + Lomb this week:

• Positive Sentiment: Strong quarterly results: Bausch + Lomb reported adjusted earnings of $0.34 per share, well above the $0.21 consensus estimate, while revenue reached approximately $1.38 billion versus expectations of $1.37 billion. Revenue increased 7.3% year over year. Bausch + Lomb Q3 2026 Earnings
• Positive Sentiment: Higher 2026 guidance: Management raised its forecast to $5.450 billion-$5.550 billion in revenue and $1.090 billion-$1.140 billion in adjusted EBITDA, citing continued momentum from its Vision ’27 strategy. The improved outlook supports investor confidence in growth and profitability. Bausch + Lomb Raises 2026 Guidance
• Positive Sentiment: Analysts raised targets: RBC lifted its price target from $21 to $23 and maintained an “outperform” rating. JPMorgan raised its target from $16 to $22, although it retained a “neutral” rating. The revisions indicate that analysts see improved earnings potential following the results. RBC Raises BLCO Price Target
• Neutral Sentiment: Deutsche Bank raised its target from $16 to $20 but kept a “hold” rating, while Wells Fargo increased its target from $18 to $19 and maintained an “equal weight” rating. These calls reflect more cautious views after the stock’s recent advance. Deutsche Bank Adjusts BLCO Price Target

Bausch + Lomb Company Profile

Bausch + Lomb Corporation (NYSE: BLCO) is a global eye-health company that develops, manufactures and markets products for vision care, ophthalmic pharmaceuticals and eye surgery. The company serves consumers, eye-care professionals, hospitals and surgical centers through a portfolio spanning contact lenses, contact-lens care products, prescription medicines, over-the-counter eye-care products and surgical equipment.

Its vision-care portfolio includes the Biotrue and INFUSE contact-lens brands, as well as solutions and other products used to clean and maintain contact lenses.